{"title":"美国食品和药物管理局批准 30 年来首个治疗精神分裂症的新疗法类别","authors":"Valerie A. Canady","doi":"10.1002/mhw.34198","DOIUrl":null,"url":null,"abstract":"<p>The U.S. Food and Drug Administration (FDA) on Sept. 26 approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for treating adult patients with schizophrenia. The move represents the first new class of treatment for this population in three decades.</p>","PeriodicalId":100916,"journal":{"name":"Mental Health Weekly","volume":"34 38","pages":"1-3"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"FDA approves first new class of treatment for schizophrenia in 30 years\",\"authors\":\"Valerie A. Canady\",\"doi\":\"10.1002/mhw.34198\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The U.S. Food and Drug Administration (FDA) on Sept. 26 approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for treating adult patients with schizophrenia. The move represents the first new class of treatment for this population in three decades.</p>\",\"PeriodicalId\":100916,\"journal\":{\"name\":\"Mental Health Weekly\",\"volume\":\"34 38\",\"pages\":\"1-3\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mental Health Weekly\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/mhw.34198\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mental Health Weekly","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mhw.34198","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
FDA approves first new class of treatment for schizophrenia in 30 years
The U.S. Food and Drug Administration (FDA) on Sept. 26 approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for treating adult patients with schizophrenia. The move represents the first new class of treatment for this population in three decades.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
